Format

Send to

Choose Destination
Therap Adv Gastroenterol. 2016 May;9(3):265-72. doi: 10.1177/1756283X15621231. Epub 2015 Dec 31.

Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: a proof-of-concept study.

Author information

1
Institute of Clinical Chemistry and Laboratory Medicine and Department of Gastroenterology, General Hospital Steyr, Sierningerstraße 170, 4400 Steyr, Austria.
2
Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Steyr, Steyr, Austria.
3
Clinical Institute of Medical and Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
4
Institute of Clinical Chemistry and Laboratory Medicine and Department of Gastroenterology, General Hospital Steyr, Steyr, Austria.

Abstract

BACKGROUND:

Diagnosis of small intestinal bacterial overgrowth (SIBO) remains challenging. This study aimed at proving the diagnostic concept of carbohydrate-specific SIBO (cs-SIBO) using glucose, fructose and sorbitol hydrogen (H2)/methane (CH4) breath testing (HMBT).

METHODS:

In this study 125 patients referred to our outpatient clinic for SIBO testing were included. All individuals underwent glucose (50 g), fructose (25 g) and sorbitol (12.5 g) HMBT at 3 consecutive days. Patients with cs-SIBO (i.e. early H2/CH4 peak) were given rifaximin (600 mg/day) in a 10-day treatment. HMBT results were reassessed in a subset of patients 3-6 months after antibiotic therapy. In view of cs-SIBO diagnosis, agreements between HMBT results obtained for different sugars were calculated using Cohen's kappa (κ) with 95% confidence intervals (CIs).

RESULTS:

A total of 59 (47.2%) patients presented an early H2/CH4 peak with one or more sugars. Among these, 21 (16.8%), 10 (8.0%) and 7 (5.6%) individuals had a positive HMBT result with either glucose, fructose or sorbitol, respectively. Another 21 (16.8%) patients with a positive glucose HMBT result were also found positive with an early H2/CH4 peak obtained after ingestion of fructose and/or sorbitol. Fair agreement was observed between glucose and fructose (κ = 0.26, p = 0.0018) and between glucose and sorbitol (κ = 0.18, p = 0.0178) HMBT results. Slight agreement was observed between fructose and sorbitol (κ = 0.03, p = 0.6955) HMBT results only. Successful antibiotic therapy with rifaximin could be demonstrated in 26/30 (86.7%) of patients as indicated by normal HMBT results and symptom remission.

CONCLUSIONS:

Combined glucose, fructose and sorbitol HMBT has the potential to optimize cs-SIBO diagnosis. Furthermore, the majority of patients with cs-SIBO seem to benefit from rifaximin therapy regardless of its carbohydrate specificity.

KEYWORDS:

carbohydrate specificity; small intestinal bacterial overgrowth diagnosis; treatment

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center